The nurse is caring for a client experiencing sympathetic nervous system stimulation. What assessment finding supports this diagnosis? Select all that apply. (Select All that Apply.)
Increased heart rate
Decrease in urinary bladder muscle tone
Increased blood pressure
Decreased salivation
Decreased bowel sounds
Correct Answer : A,C
A. Increased heart rate: Sympathetic nervous system stimulation typically leads to increased heart rate as part of the "fight or flight" response.
B. Decrease in urinary bladder muscle tone: Sympathetic stimulation would typically cause relaxation of the urinary bladder, leading to increased muscle tone.
C. Increased blood pressure: Sympathetic nervous system activation results in vasoconstriction and increased cardiac output, leading to elevated blood pressure.
D. Decreased salivation: Sympathetic stimulation can lead to decreased salivation as part of the "fight or flight" response, but it's not a consistent finding.
E. Decreased bowel sounds: Sympathetic activation can inhibit gastrointestinal motility, leading to decreased bowel sounds, but it's not a universal finding in sympathetic stimulation.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is D
Explanation
A. Tachycardia is not typically associated with cholinergic drug effects. Cholinergic stimulation tends to slow down the heart rate rather than increase it.
B. Palpitations may occur with certain cardiac arrhythmias or in response to sympathetic stimulation, but they are not typically associated with cholinergic drug effects.
C. Cholinergic drugs are more likely to cause vasodilation rather than vasoconstriction.
Therefore, vasoconstriction is not a common cardiovascular effect of cholinergic drug therapy.
D. Bradycardia is a common cardiovascular effect of cholinergic drug therapy. Cholinergic stimulation slows down the heart rate by increasing parasympathetic activity, particularly at the
sinoatrial (SA) node. Therefore, bradycardia is the cardiovascular effect that nurses should monitor for when administering cholinergic drugs.
Correct Answer is A
Explanation
A. Carbidopa prevents the breakdown of levodopa in the periphery, specifically in the gastrointestinal tract and peripheral tissues, allowing more levodopa to reach the brain and be converted to dopamine. This enhances the effectiveness of levodopa therapy in managing the symptoms of Parkinson's disease.
B. Carbidopa is not the biologic precursor of dopamine. It is a peripheral decarboxylase inhibitor that does not cross the blood-brain barrier.
C. Carbidopa does not directly allow for larger doses of levodopa to be given. However, by
inhibiting the peripheral breakdown of levodopa, it enhances the availability of levodopa to the central nervous system, potentially improving therapeutic efficacy.
D. While levodopa-carbidopa combination therapy may have fewer drug-food interactions compared to levodopa alone, the primary reason for combining these medications is to enhance the effectiveness of levodopa by preventing its peripheral breakdown.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.